Nuvaira, based on research by a then-professor at Washington University School of Medicine, has closed a $79m funding round led by US Venture Partners.
Nuvaira, a US-based developer of treatments for obstructive lung diseases, closed a $79m series E round on Monday led by venture capital firm US Venture Partners.
The round also featured venture capital firms Endeavour Vision, Qiming Venture Partners, Lightstone Ventures, Advanced Technology Ventures (ATV), Split Rock Partners and Windham Venture Partners as well as philanthropic outfit Richard King Mellon Foundation.
Investment firms Morgenthaler Ventures and company builder Versant Ventures also took part, as did Vertex Venture, the venture capital arm of Singaporean government-owned investment firm Temasek.
Nuvaira has developed a platform, called Lung Denervation System, that aims to tackle chronic lung diseases such as asthma and chronic obstructive pulmonary disease, by targeting overactive airway nerves.
The company was founded in 2008 as Innovative Pulmonary Solutions and first rebranded to Holaira before settling on its current name, Nuvaira, in 2017.
Nuvaira was founded by Martin Mayse,…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
